Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
A Open-Label Phase in Participants With Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
GMMG-HD11/DSMM XXI/64007957MMY3010
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
- Status
- RECRUITING
- Phase
- PHASE3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Status
- RECRUITING
- Phase
- PHASE3
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Status
- RECRUITING
- Phase
- PHASE1
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
- Status
- RECRUITING
- Phase
- PHASE2
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
- Status
- RECRUITING
- Phase
- PHASE2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
- Status
- RECRUITING
- Phase
- PHASE2